{
    "id": "61f93e68882a024a1000004d",
    "question": "Should perampanel be used for amyotrophic lateral sclerosis?",
    "options": {
        "A": "yes",
        "B": "no"
    },
    "answer": "B",
    "predict": "{\"step_by_step_thinking\": \"To answer this question, let's analyze the information provided from the relevant documents. Document [2] mentions that gabapentin is a spasmolytic agent that has shown promise in relieving muscle spasm, and Document [6] mentions that perampanel is an AMPA receptor antagonist that may be useful in relieving painful disorders that involve muscle spasm. However, there is no direct information in the provided documents about the use of perampanel for amyotrophic lateral sclerosis (ALS). Document [12] mentions that ALS is characterized by abnormal high signal intensity within the corticospinal tracts on MRI, and Document [26] describes the clinical manifestations of ALS, including muscle weakness, fasciculations, and respiratory muscle involvement. Given this information, we can infer that ALS is a neurodegenerative disorder that affects the motor neurons, leading to muscle weakness, fasciculations, and respiratory muscle involvement. While perampanel may have potential in relieving muscle spasm, there is no direct evidence to suggest its use in treating ALS. Furthermore, Document [24] mentions that antiseizure drugs are primarily used to treat epilepsy, not neurodegenerative disorders like ALS. Therefore, based on the available information, the correct answer is B. no.\", \"answer_choice\": \"B\"}",
    "snippets": [
        {
            "id": "Neurology_Adams_9011",
            "title": "Neurology_Adams",
            "content": "Mercuri E, Darras BT, Chiriboga CA, et al: Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med 378:625, 2018. Mesulam MM: Primary progressive aphasia\u2014a language-based dementia. N Engl J Med 349:1535, 2003. Mesulam MM: Slowly progressive aphasia without generalized dementia. Ann Neurol 11:592, 1982. Miller RG, Jackson CE, Kasarskis EJ, et al: Practice parameter update: The care of the patient with amyotrophic lateral sclerosis: Multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 73:1227, 2009a. Miller RG, Jackson CE, Kasarskis EJ, et al: Practice parameter update: The care of the patient with amyotrophic lateral sclerosis: Drug, nutritional, and respiratory therapies (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 73:1218, 2009b."
        },
        {
            "id": "Neurology_Adams_9803",
            "title": "Neurology_Adams",
            "content": "conditions such as neuropathy and amyotrophic lateral sclerosis (ALS) may be mistakenly attributed to this innocuous finding. The levels return to normal within a few months of abstaining from fish."
        },
        {
            "id": "Pharmacology_Katzung_2941",
            "title": "Pharmacology_Katzung",
            "content": "Gabapentin is an antiepileptic drug (see Chapter 24) that has shown considerable promise as a spasmolytic agent in several studies involving patients with multiple sclerosis. Pregabalin is a newer analog of gabapentin that may also prove useful in relieving painful disorders that involve a muscle spasm component. Progabide and glycine have also been found in preliminary studies to reduce spasticity. Progabide is a GABAA and GABAB agonist and has active metabolites, including GABA itself. Glycine is another inhibitory amino acid neurotransmitter (see Chapter 21) that appears to possess pharmacologic activity when given orally and readily passes the blood-brain barrier. Idrocilamide and riluzole are newer drugs for the treatment of amyotrophic lateral sclerosis (ALS) that appear to have spasm-reducing effects, possibly through inhibition of glutamatergic transmission in the CNS."
        },
        {
            "id": "Pharmacology_Katzung_2536",
            "title": "Pharmacology_Katzung",
            "content": "The most significant drug interactions with perampanel are with potent CYP3A4 inducer antiseizure drugs such as carbamazepine, oxcarbazepine, and phenytoin. Concomitant use with such agents increases the clearance of perampanel by 50\u201370%, which may require the use of higher perampanel doses. Of somewhat lesser concern is the potential for strong CYP3A4 inhibitors to increase the levels of perampanel. Perampanel may decrease the effectiveness of levonorgestrel-containing hormonal contraceptives."
        },
        {
            "id": "Pharmacology_Katzung_2534",
            "title": "Pharmacology_Katzung",
            "content": "A typical maintenance dose of perampanel for patients 12 years of age and older is 4, 6, or 8 mg/d. Higher doses may be needed in patients who are receiving CYP3A4-inducing antiseizure drugs. Perampanel use is often associated with behavioral adverse reactions including aggression, hostility, irritability, and anger. The frequency of these adverse effects increases in a dose-dependent fashion, and they occur more often in younger patients and in those with learning disabilities or dementia. Alcohol use may exacerbate the level of anger. Other common adverse effects are dizziness, somnolence, and headache. Falls are more common at higher doses."
        },
        {
            "id": "Neurology_Adams_10795",
            "title": "Neurology_Adams",
            "content": "either with the neuropathy or in isolation, the corpora amylacea are found throughout the cerebrum. The process is detailed by Robitaille and colleagues and an upper motor neuron presentation that simulates amyotrophic lateral sclerosis, by McDonald and coworkers."
        },
        {
            "id": "Pharmacology_Katzung_2533",
            "title": "Pharmacology_Katzung",
            "content": "of excitation to distant sites is mediated by AMPA receptors at the excitatory synapses that long axons make on their distant targets. Perampanel is therefore well suited to inhibit this spread of excitation, which may account for its activity in preventing secondary and primary generalized convulsive seizures. Perampanel binds to an allosteric site on the extracellular side of the channel, acting as a wedge to prevent channel opening."
        },
        {
            "id": "Neurology_Adams_8857",
            "title": "Neurology_Adams",
            "content": "History Credit for the original delineation of amyotrophic lateral sclerosis is appropriately given to Charcot. With Joffroy in 1869 and Gombault in 1871, he studied the pathologic aspects of the disease. In a series of lectures given from 1872 to 1874, he provided a lucid account of the clinical and pathologic findings. Although called Charcot disease in France, amyotrophic lateral sclerosis (the term recommended by Charcot) has been preferred in the English-speaking world. Duchenne had earlier (1858) described labioglossolaryngeal paralysis, a term that Wachsmuth in 1864 changed to progressive bulbar palsy. In 1869, Charcot called attention to the nuclear origin of progressive bulbar palsy, and in 1882 Dejerine established its relationship to ALS. Most authors credit Aran and Duchenne with the earliest descriptions of progressive spinal muscular atrophy, which they believed to be of myogenic origin. This interpretation was, of course, incorrect; Cruveilhier, a few years later, noted"
        },
        {
            "id": "Pharmacology_Katzung_2042",
            "title": "Pharmacology_Katzung",
            "content": "neurotransmitter release, thereby regulating synaptic plasticity, the process of synapse strengthening that underlies learning and memory. Because aberrant NMDA receptor activation and excessive NO synthesis is linked to excitotoxic neuronal death in several neurologic diseases, including stroke, amyotrophic lateral sclerosis, and Parkinson\u2019s disease, therapy with NOS inhibitors may reduce neuronal damage in these conditions. However, clinical trials have not clearly supported any benefit of NOS inhibition, which may reflect nonselectivity of the inhibitors, resulting in inhibition of the beneficial effects of eNOS."
        },
        {
            "id": "Neurology_Adams_12066",
            "title": "Neurology_Adams",
            "content": "that there is no serious disease. We have found it useful to list the diseases that have been excluded by examination and testing: brain tumor, stroke, amyotrophic lateral sclerosis, multiple sclerosis, etc. This often evokes an acknowledgment by the patient that one of the diseases had been a preoccupying concern. We then indicate, without using psychologic terms, that the brain may at times adopt certain patterns of behavior that do not reflect structural damage, and, furthermore, that these patterns can be unlearned with physical therapy and time, as described in the following text."
        },
        {
            "id": "Neurology_Adams_7381",
            "title": "Neurology_Adams",
            "content": "General Measures in the Treatment of MS Fatigue, a common complaint of MS patients, particularly in relation to acute attacks, responds to some extent to amantadine (100 mg morning and noon), modafinil (200 to 400 mg/d), pemoline (20 to 75 mg each morning), methylphenidate, or dextroamphetamine. For depression associated with the disease, there does not seem to be any superior antidepressant and donepezil has not been found to be helpful for cognitive problems. Agents such as 4-aminopyridine improve conduction through demyelinated central nerve fibers by blocking potassium channels. In some patients these drugs have shown measureable improvements in gait. They are pro-convulsant and should be avoided in individuals at risk of seizures."
        },
        {
            "id": "Neurology_Adams_4135",
            "title": "Neurology_Adams",
            "content": "hypoxic-hypotensive encephalopathy, amyotrophic lateral sclerosis, and multiple sclerosis, as already indicated; but in a number of less-common processes, such as progressive supranuclear palsy and Wilson disease, it may be quite a prominent feature. Abrupt onset, of course, points to vascular disease."
        },
        {
            "id": "Pharmacology_Katzung_2532",
            "title": "Pharmacology_Katzung",
            "content": "Perampanel is a potent noncompetitive antagonist of the AMPA receptor, a subtype of the ionotropic glutamate receptor that is the main mediator of synaptic excitation in the central nervous system (Figure 24\u20131). AMPA receptors are critical to local generation of seizure activity in epileptic foci and are also responsible for the neuron-to-neuron spread of excitation. Partial blockade of AMPA receptors by therapeutic concentrations of perampanel reduces the likelihood of seizure occurrence. In generalized convulsive seizures, whether occurring as a secondarily generalized convulsion following a focal seizure or as a primary generalized seizure, excitatory cortical neurons engage subcortical centers, including the thalamus, that relay the excitation throughout both hemispheres. This spread of excitation to distant sites is mediated by AMPA receptors at the excitatory synapses that long axons make on their distant targets. Perampanel is therefore well suited to inhibit this spread of"
        },
        {
            "id": "Neurology_Adams_8980",
            "title": "Neurology_Adams",
            "content": "Bharucha NE, Bharucha EP, Bhabha SR: Machado-Joseph-Azorean disease in India. Arch Neurol 43:142, 1986. Blackstone C: Cellular pathways of hereditary spastic paraplegia. Ann Rev Neurosci 35:25, 2012. Bonduelle M: Amyotrophic lateral sclerosis. In: Vinken RT, Bruyn GW (eds): Handbook of Clinical Neurology. Vol 29. Amsterdam, North Holland, 1975, pp 281\u2013338. Braak H, Del Tredici K: Nervous system pathology in sporadic Parkinson disease. Neurology 70:1916, 2008. Bradley WG, Good P, Rasool CG, et al: Morphometric and biochemical studies of peripheral nerves in amyotrophic lateral sclerosis. Ann Neurol 14:267, 1983. Brandt S: Werdnig-Hoffmann\u2019s Infantile Progressive Muscular Atrophy. Thesis: Vol 22. Copenhagen, Munksgaard, 1950. Breedveld GJ, Percy AK, MacDonald ME, et al: Clinical and genetic heterogeneity in benign hereditary chorea. Neurology 59:579, 2002. Brice A: Genetics of Parkinson\u2019s disease: LRRK2 on the rise. Brain 128:2760, 2005."
        },
        {
            "id": "InternalMed_Harrison_29565",
            "title": "InternalMed_Harrison",
            "content": "The findings may provide a guide to the severity of an acute disorder of a peripheral or cranial nerve (by indicating whether denervation has occurred and the completeness of the lesion) and whether the pathologic process is active or progressive in chronic or degenerative disorders such as amyotrophic lateral sclerosis. Such information is important for prognostic purposes."
        },
        {
            "id": "Pharmacology_Katzung_3221",
            "title": "Pharmacology_Katzung",
            "content": "Lamotrigine is approved as a maintenance treatment for bipolar disorder. Although not effective in treating acute mania, it appears effective in reducing the frequency of recurrent depressive cycles and may have some utility in the treatment of bipolar depression. A number of novel agents are under investigation for bipolar depression, including riluzole, a neuroprotective agent that is approved for use in amyotrophic lateral sclerosis; ketamine, a noncompetitive NMDA antagonist previously discussed as a drug believed to model schizophrenia but thought to act by producing relative enhancement of AMPA receptor activity; and AMPA receptor potentiators. SUMMARY Antipsychotic Drugs & Lithium Subclass, Drug Mechanism of Action Effects Clinical Applications Pharmacokinetics, Toxicities, Interactions"
        },
        {
            "id": "Neurology_Adams_2639",
            "title": "Neurology_Adams",
            "content": "It is difficult to give definitive guidance on combining medications for refractory seizures. Several general principles are worth noting. First, it may seem sensible to avoid drug combinations with similar putative mechanisms because their side effects may be additive, for example, the addition of lamotrigine to carbamazepine or of phenytoin to carbamazepine may not be ideal but at the same time, it should be mentioned that the mechanism of action has little influence on clinical effectiveness and drugs of a similar class are often combined. Second, the clinician should be aware of known interactions through metabolic pathways such as valproate combined with either lamotrigine or phenobarbital as they share the cytochrome P450 degradation pathway. Third, although it is appropriate to use drugs that are known to be effective for the class of seizures under treatment, it is often necessary to extend the choices beyond these restrictions."
        },
        {
            "id": "Neurology_Adams_7351",
            "title": "Neurology_Adams",
            "content": "In addition to the available treatments discussed below, a current list of clinical trials is maintained by the National Multiple Sclerosis Society: http://www.nationalmssociety.org/research/clinical-trials/clinical-trials-in-ms/index .aspx"
        },
        {
            "id": "Neurology_Adams_2693",
            "title": "Neurology_Adams",
            "content": "In an epileptic patient known to be taking seizure medications chronically but in whom the serum level of drug is unknown, it is probably best to administer the full-recommended dose of phenytoin. If it can be established that the serum phenytoin is above 10 mg/mL, a lower loading dose may be advisable. If seizures continue, an additional 5 mg/kg is indicated. If this fails to suppress the seizures and status has persisted for 20 to 30 min, an endotracheal tube should be inserted and O2 administered. Having emphasized the dangers of this syndrome, at each stage of treatment it is worthwhile considering if a refractory convulsive episode is of psychogenic, nonepileptic nature. The reader is referred to the previous section on this subject."
        },
        {
            "id": "Pharmacology_Katzung_2960",
            "title": "Pharmacology_Katzung",
            "content": "Staals LM et al: Reduced clearance of rocuronium and sugammadex in patients with severe to end-stage renal failure: A pharmacokinetic study. Br J Anaesth 2010;104:31. Sugammadex: BRIDION (sugammadex) Injection, for intravenous use initial U.S. Approval: 2015. Retrieved from http://www.accessdata.fda.gov/drugsatfda_docs/ label/2015/022225lbl.pdf. Sunaga H et al: Gantacurium and CW002 do not potentiate muscarinic receptor-mediated airway smooth muscle constriction in guinea pigs. Anesthesiology 2010;112:892. Viby-Mogensen J: Neuromuscular monitoring. In: Miller RD (editor): Anesthesia, 5th ed. Churchill Livingstone, 2000. Caron E, Morgan R, Wheless JW: An unusual cause of flaccid paralysis and coma: Baclofen overdose. J Child Neurol 2014;29:555. Corcia P, Meininger V: Management of amyotrophic lateral sclerosis. Drugs 2008;68:1037. Cutter NC et al: Gabapentin effect on spasticity in multiple sclerosis: A placebo-controlled, randomized trial. Arch Phys Med Rehabil 2000;81:164."
        },
        {
            "id": "Neurology_Adams_228",
            "title": "Neurology_Adams",
            "content": "of stroke, multiple sclerosis, and amyotrophic lateral sclerosis. Although the degree of functional deficit does not precisely correlate with the degree of electrophysiologic change, one expects that refinements of this technique may be useful in evaluating the status of the corticospinal motor system as well as other cortically based functions."
        },
        {
            "id": "Neurology_Adams_6027",
            "title": "Neurology_Adams",
            "content": "that Sigurdsson and Rida first used the term slow virus infection to describe long incubation periods during which the animals appeared well; and (4) the demonstration by electron microscopy of viral particles in the lesions of progressive multifocal leukoencephalopathy and, later, isolation of virus from the lesions. The suggestion that the late onset of progressive weakness after poliomyelitis (\u201cpostpolio syndrome\u201d) might represent a slow infection has never been verified. Claims have also been made numerous times over the years for a viral causation of multiple sclerosis, amyotrophic lateral sclerosis, and other degenerative diseases, but the evidence in all instances has been questionable."
        },
        {
            "id": "InternalMed_Harrison_30550",
            "title": "InternalMed_Harrison",
            "content": "FIGURE 452-1 Amyotrophic lateral sclerosis. Axial T2-weighted magnetic resonance imaging (MRI) scan through the lateral ventricles of the brain reveals abnormal high signal intensity within the corticospinal tracts (arrows). This MRI feature represents an increase in water content in myelin tracts undergoing Wallerian degeneration secondary to cortical motor neuronal loss. This finding is commonly present in ALS, but can also be seen in AIDS-related encephalopathy, infarction, or other disease processes that produce corticospinal neuronal loss in a symmetric fashion."
        },
        {
            "id": "Pharmacology_Katzung_2535",
            "title": "Pharmacology_Katzung",
            "content": "Perampanel has a long half-life, typically ranging from 70 to 110 hours, which permits once-daily dosing. Because of the long half-life, steady state is not achieved for 2\u20133 weeks; the prescriber should make dosage changes no more frequently than at 2-week (or longer) intervals. The kinetics are linear in the dose range of 2\u201312 mg/d. The half-life is prolonged in moderate hepatic failure. Absorption is rapid and the drug is fully bioavailable. Although food slows the rate of absorption, the extent is not affected. Perampanel is 95% bound to plasma proteins. The drug is extensively metabolized via initial oxidation by CYP3A4 and subsequent glucuronidation."
        },
        {
            "id": "Pharmacology_Katzung_2465",
            "title": "Pharmacology_Katzung",
            "content": "Antiseizure drugs must have reasonable oral bioavailability and must enter the central nervous system. These drugs are predominantly distributed into total body water. Plasma clearance is relatively slow; many antiseizure drugs are therefore considered to be medium to long acting, such that they are administered twice or three times a day. Some have half-lives longer than 12 hours. A few, such as zonisamide and perampanel, can often be administered once daily. For some drugs with short half-lives, extended-release preparations are now available; as a result, compliance is better. In the remainder of the chapter, the most widely used anti-seizure drugs, as well as some that are used only in special circumstances, are reviewed. The focal (partial onset) seizure medications are described first, followed by medications for generalized onset seizures and certain epileptic syndromes."
        },
        {
            "id": "Pharmacology_Katzung_2531",
            "title": "Pharmacology_Katzung",
            "content": "Coadministration of brivaracetam with carbamazepine may increase exposure to carbamazepine epoxide, the active metabolite of carbamazepine, possibly leading to adverse effects; carbamazepine dose reduction should be considered. Similarly, coadministration of brivaracetam with phenytoin may increase phenytoin levels. Coadministration of other antiseizure drugs is unlikely to affect brivaracetam exposure. Brivaracetam provides no added therapeutic benefit when administered in conjunction with levetiracetam; both drugs act on SV2A. Perampanel is an orally active AMPA receptor antagonist approved for the treatment of focal seizures and primary generalized tonicclonic seizures in idiopathic generalized epilepsies. Mechanism of Action"
        },
        {
            "id": "Pathology_Robbins_5160",
            "title": "Pathology_Robbins",
            "content": "The disease affects men slightly more frequently than women and becomes clinically manifest in the fifth decade or later. It usually begins with subtle asymmetric distal extremity weakness. As the disease progresses, muscle strength and bulk diminish, and involuntary contractions of individual motor units, termed fasciculations, occur. The disease eventually involves the respiratory muscles, leading to recurrent bouts of pulmonary infection, which is the usual cause of death. The balance between upper and lower motor neuron involvement can vary, although most patients exhibit involvement of both. In some patients, degeneration of the lower brain stem cranial motor nuclei occurs early and progresses rapidly, a pattern of disease referred to as bulbar amyotrophic lateral sclerosis. With this disease pattern, abnormalities of swallowing and speaking dominate."
        },
        {
            "id": "Neurology_Adams_336",
            "title": "Neurology_Adams",
            "content": "Figure 2-18. Abnormal spontaneous activity. A. Positive sharp waves and fibrillations recorded from a paralyzed, denervated muscle. A typical positive sharp wave is seen above the star. The fibrillations (arrow) are 1 to 2 ms in duration, 100 to 300 mV in amplitude, and largely negative (upward) in polarity following an initial positive deflection. B. Fasciculation. This spontaneous motor unit potential was recorded from a patient with amyotrophic lateral sclerosis. It has a serrated configuration and it fired once every second or two. Calibrations: 5 ms (horizontal) and 200 \u03bcV in A; 1 mV in B (vertical)."
        },
        {
            "id": "Pharmacology_Katzung_2955",
            "title": "Pharmacology_Katzung",
            "content": "Succinylcholine Generic, Anectine, Quelicin Vecuronium Generic, Norcuron SPASMOLYTICS, ANTISPASMODICS Baclofen Generic, Lioresal, Gablofen Botulinum toxin type A Botox, Dysport, Xeomin Carisoprodol Generic, Soma, Vanadom Cyclobenzaprine Generic, Amrix, Fexmid, Flexeril Dantrolene Generic, Dantrium, Revonto Diazepam Generic, Valium, Diastat Gabapentin Generic, Neurontin, Gabarone Note: This drug is labeled for use only in epilepsy and postherpetic neuralgia. Metaxalone Generic, Skelaxin Methocarbamol Generic, Robaxin Orphenadrine Generic, Norflex, others Riluzole Generic, Rilutek Note: This drug is labeled only for use in amyotrophic lateral sclerosis. Tizanidine Generic, Zanaflex Belmont MR et al: Clinical pharmacology of GW280430A in humans. Anesthesiology 2004;100:768. Brull SJ, Murphy GS: Residual neuromuscular block: Lessons unlearned. Part II: Methods to reduce the risk of residual weakness. Anesth Analg 2010;111:129."
        },
        {
            "id": "Neurology_Adams_11888",
            "title": "Neurology_Adams",
            "content": "A few random fasciculations in the muscles of the calf, small muscles of the hand or of the face, or elsewhere are seen in most normal individuals. They are of little significance but can be a source of worry to physicians and patients who have read that fasciculations are an early sign of amyotrophic lateral sclerosis. A simple clinical rule is that fasciculations in relaxed muscle are not indicative of motor system disease unless there is associated weakness, atrophy, or reflex change."
        },
        {
            "id": "Neurology_Adams_3989",
            "title": "Neurology_Adams",
            "content": "Fatigue of varying degree is also a regular feature of all diseases that are marked by denervation of muscle and loss of muscle fibers. Fatigue in these cases is a result of the excessive work imposed on the remaining intact muscle (overwork fatigue). This is most characteristic of amyotrophic lateral sclerosis and the postpolio syndrome, but it also occurs in patients as they are recovering from Guillain-Barr\u00e9 syndrome and in those with chronic polyneuropathy."
        },
        {
            "id": "Neurology_Adams_1595",
            "title": "Neurology_Adams",
            "content": "with almost immediate and remarkable relief of severe pain, we are uncertain of the best course but acknowledge that this is probably not an effective treatment for the majority of patients. Further discussion can be found in the review by Ensrud and Schousboe."
        }
    ],
    "scores": [
        0.025027131312342514,
        0.024656043190525948,
        0.024227175413673745,
        0.023950737319721277,
        0.022905459175553082,
        0.0204341337674671,
        0.01960972796308757,
        0.019324122479462285,
        0.019311462750766617,
        0.01904761904761905,
        0.018596642272922945,
        0.018433571185864764,
        0.01823607427055703,
        0.018018018018018018,
        0.017740429505135387,
        0.017157397310069065,
        0.016483516483516484,
        0.0161907190209077,
        0.016145371660124096,
        0.016095669036845506,
        0.01572108133194106,
        0.015568931589304318,
        0.014925373134328358,
        0.014625850340136054,
        0.014493514677309248,
        0.014288559195459525,
        0.01412512218963832,
        0.013946869070208728,
        0.013571954361428044,
        0.013303378705783886,
        0.013133287997279836,
        0.013098068660576482
    ]
}